Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632252 | 0.83 | KDM4E (0.46) | GAAMAPT | |
| SCHEMBL24816446 | 0.81 | DGAT1 (0.33) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL19972103 | 0.81 | DGAT1 (0.35) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL31511111 | 0.81 | DGAT1 (0.33) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL31511113 | 0.81 | DGAT1 (0.33) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL28966397 | 0.81 | DGAT1 (0.34) | DGAT1PDE10ANPC1 | |
| SCHEMBL15656304 | 0.81 | DGAT1 (0.39) | DGAT1PDE10ANPC1 | |
| SCHEMBL24816444 | 0.80 | NPC1 (0.33) | DGAT1NPC1ALOX5APFEN1 | |
| SCHEMBL25179891 | 0.79 | DGAT1 (0.34) | DGAT1PDE10ANPC1 | |
| SCHEMBL25183328 | 0.79 | POLB (0.35) | DGAT1MAPTPDE10ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4093736-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2022-11-30 | — | — | EP | disclosed |
| CN-109890822-B | Inhibitors of cellular metabolic processes | 安吉奥斯医药品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | DGAT1 3811/4885GAA 2659/4885MAPT 1001/4885 |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | DGAT1 4777/4885GAA 4594/4885MAPT 2730/4885 |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | DGAT1 4836/4885GAA 4248/4885MAPT 2192/4885 |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | CDK2, CDK1, CCNK | DGAT1 2569/4885GAA 1679/4885MAPT 2518/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | DGAT1 4777/4885GAA 4594/4885MAPT 2730/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | DGAT1 3804/4885GAA 2715/4885MAPT 1204/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | DGAT1 2671/4885GAA 968/4885MAPT 1914/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | DGAT1 2671/4885GAA 968/4885MAPT 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.